Avidity Biosciences (NASDAQ:RNA – Get Free Report) and Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings.
Risk and Volatility
Avidity Biosciences has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.7, indicating that its share price is 170% more volatile than the S&P 500.
Profitability
This table compares Avidity Biosciences and Cardio Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avidity Biosciences | -3,650.39% | -44.92% | -39.57% |
| Cardio Diagnostics | -40,612.50% | -71.75% | -66.25% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avidity Biosciences | 1 | 12 | 5 | 1 | 2.32 |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
Avidity Biosciences currently has a consensus price target of $69.42, indicating a potential upside of 416.53%. Given Avidity Biosciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe Avidity Biosciences is more favorable than Cardio Diagnostics.
Earnings and Valuation
This table compares Avidity Biosciences and Cardio Diagnostics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avidity Biosciences | $18.62 million | N/A | -$322.30 million | N/A | N/A |
| Cardio Diagnostics | $14,825.00 | 407.31 | -$6.50 million | ($3.72) | -0.55 |
Cardio Diagnostics has lower revenue, but higher earnings than Avidity Biosciences.
Institutional and Insider Ownership
8.1% of Cardio Diagnostics shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by insiders. Comparatively, 13.3% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Avidity Biosciences beats Cardio Diagnostics on 8 of the 13 factors compared between the two stocks.
About Avidity Biosciences
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Avidity Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avidity Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
